Mackenzie Financial Corp Acquires 55,535 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mackenzie Financial Corp increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 190.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 84,662 shares of the biotechnology company's stock after acquiring an additional 55,535 shares during the period. Mackenzie Financial Corp's holdings in BioCryst Pharmaceuticals were worth $637,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $33,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of BioCryst Pharmaceuticals by 3.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company's stock worth $3,016,000 after acquiring an additional 11,581 shares during the last quarter. Woodline Partners LP acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $3,385,000. Two Sigma Advisers LP lifted its position in shares of BioCryst Pharmaceuticals by 14.6% during the fourth quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock worth $18,799,000 after purchasing an additional 318,800 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of BioCryst Pharmaceuticals by 0.8% during the fourth quarter. Two Sigma Investments LP now owns 1,774,214 shares of the biotechnology company's stock worth $13,342,000 after purchasing an additional 13,406 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Up 0.5%

NASDAQ BCRX traded up $0.06 during trading hours on Friday, hitting $11.04. The company's stock had a trading volume of 4,093,323 shares, compared to its average volume of 3,039,169. The stock has a fifty day moving average of $9.00 and a 200 day moving average of $8.27. The firm has a market capitalization of $2.31 billion, a P/E ratio of -18.10 and a beta of 1.11. BioCryst Pharmaceuticals, Inc. has a twelve month low of $5.92 and a twelve month high of $11.31.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BCRX shares. Needham & Company LLC upped their target price on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Barclays upped their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Royal Bank of Canada reiterated an "outperform" rating and set a $13.00 target price (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.